Ally Bridge is investment in best or first-in-class technologies and therapies across the medtech and biotech sectors. Within medtech, Ally Bridge is investing in high-growth companies with technologies validated by strong clinical results and regulatory approval(s), and operating in large markets. Within biotech, Ally Bridge is investing across the development and commercial spectrum through its distinct private and public strategies.
Ally Bridge is investment in best or first-in-class technologies and therapies across the medtech and biotech sectors. Within medtech, Ally Bridge is investing in high-growth companies with technologies validated by strong clinical results and regulatory approval(s), and operating in large markets. Within biotech, Ally Bridge is investing across the development and commercial spectrum through its distinct private and public strategies.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
ABG’s private equity strategy is focused primarily across medtech and biotech, with a focus on later-stage growth and venture investments. ABG plays an active role in each of its investments, providing a strategic voice and guidance across all core functions. ABG primarily focuses on opportunities within North America and Europe, while maintaining a global perspective.
ABG manages a series of public equity funds, which invest across all types of publicly-traded companies primarily within the US therapeutics vertical.
Our DNA lies in a focused dedication to high-impact life science innovation combining scientific and clinical expertise with financial and capital markets knowledge to invest across private equity and public markets in best or first-in-class technologies and therapies that address unmet medical needs. We provide value by generating superior risk-adjusted returns for investors while supporting groundbreaking advancements in medtech and biotech through strategic funding, industry network, and active board involvement in portfolio companies.
We are fully dedicated to finding solutions to the untreatable, through both a therapeutics and technology lens.
We are at the forefront of promoting the best and first-in-class solutions globally, through integrity and hard work.
Transforming healthcare and improving patient lives.
We encompass a spirit of collaboration and family across all our relationships – across the ABG team, our portfolio partners, and our Limited Partners.
< Drag>
Reach out to discuss investments in companies at the development and commercial stages.